产品说明书

Ginsenoside Re

Print
Chemical Structure| 52286-59-6 同义名 : 人参皂甙 Re ;Panaxoside Re;Ginsenoside B2;NSC 308877;Chikusetsusaponin Ivc;Sanchinoside Re
CAS号 : 52286-59-6
货号 : A149220
分子式 : C48H82O18
纯度 : 98%
分子量 : 947.154
MDL号 : MFCD00133369
存储条件：

粉末 Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(52.79 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • JNK
描述 Ginsenoside Re is an extract from Panax notoginseng. Ginsenoside Re decreased the Aβ(β-amyloid protein) levels in N2a/APP695 cells. Ginsenoside Re decreased the BACE1 (β-site amyloid precursor protein cleaving enzyme 1) mRNA and protein levels and inhibited BACE1 activity in the N2a/APP695 cells. Ginsenoside Re significantly increased the PPARγ protein and mRNA levels[3]. Ginsenoside Re can improve isoproterenol-induced myocardial fibrosis and heart failure by regulation of the TGF-β1(transforming growth factor)/Smad3 pathway[4]. GRe protects MA-induced (methamphetamine) dopaminergic neurotoxicity via upregulatgion of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated NK1 R (neurokinin 1 receptor) [5]. Moreover, ginsenoside Re-dependent upregulation of GPX4 (glutathione peroxidase 4) reduces oxidative stress and thereby alleviates 6-OHDA(6-hydroxydopamine)-induced neuronal damage[6]. After GS-Re treatment, the vessel lumen of injured vessels showed significant increases in the GS-Re 25.0 and 50.0 mg/kg/d (intermediate- and high-dose) groups according to H.E. staining. GS-Re can suppress balloon injury-induced vascular neointimal hyperplasia by inhibiting VSMC proliferation[7].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.06mL

0.21mL

0.11mL

5.28mL

1.06mL

0.53mL

10.56mL

2.11mL

1.06mL
参考文献

[1]Wang L, Yuan D, et al. Ginsenoside Re Promotes Nerve Regeneration by Facilitating the Proliferation, Differentiation and Migration of Schwann Cells via the ERK- and JNK-Dependent Pathway in Rat Model of Sciatic Nerve Crush Injury. Cell Mol Neurobiol. 2015 Aug;35(6):827-40.

[2]Sukrittanon S, Watanapa WB, Ruamyod K. Ginsenoside Re enhances small-conductance Ca(2+)-activated K(+) current in human coronary artery endothelial cells. Life Sci. 2014 Oct 12;115(1-2):15-21.

[3]Cao G, Su P, Zhang S, et al. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J Pharmacol. 2016;793:101-108

[4]Wang QW, Yu XF, Xu HL, Zhao XZ, Sui DY. Ginsenoside Re Improves Isoproterenol-Induced Myocardial Fibrosis and Heart Failure in Rats. Evid Based Complement Alternat Med. 2019;2019:3714508. Published 2019 Jan 1

[5]Dang DK, Shin EJ, Kim DJ, et al. Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor. J Neuroinflammation. 2018;15(1):52. Published 2018 Feb 21

[6]Lee GH, Lee WJ, Hur J, Kim E, Lee HG, Seo HG. Ginsenoside Re Mitigates 6-Hydroxydopamine-Induced Oxidative Stress through Upregulation of GPX4. Molecules. 2020;25(1):188. Published 2020 Jan 2

[7]Gao Y, Gao CY, Zhu P, et al. Ginsenoside Re inhibits vascular neointimal hyperplasia in balloon-injured carotid arteries through activating the eNOS/NO/cGMP pathway in rats. Biomed Pharmacother. 2018;106:1091-1097